A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain - Full Text View

Sponsored by:	Duramed Research
Information provided by:	Duramed Research
ClinicalTrials.gov Identifier:	NCT00196365

Purpose

This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9 months. Patients will be required to record menstrual pain in a daily diary.

Condition	Intervention	Phase
Dysmenorrhea	Drug: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets Drug: levonorgestrel/EE 0.15/0.03 mg tablets and placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Study to Compare the Efficacy of an Extended-Cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-Free Interval Compared to Conventional Oral Contraceptive Therapy for Cyclic Pelvic Pain

Resource links provided by NLM:

MedlinePlus related topics: Menstruation Pelvic Pain

Drug Information available for: Levonorgestrel

U.S. FDA Resources

Further study details as provided by Duramed Research:

Primary Outcome Measures:

Change from baseline in the clinical assessment of dysmenorrhea [ Time Frame: Baseline to Week 4,8,12,24, and 26 or early discontinuation ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change from baseline in clinical assessment of dysmenorrhea (assessment of 4 additional symptoms) [ Time Frame: Baseline to Weeks 4, 8, 12, 24 and 26 or early discontinuation ] [ Designated as safety issue: No ]
Incidence of menstrual bleeding and/or spotting [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
Analgesic use [ Time Frame: Duration of study ] [ Designated as safety issue: No ]

Enrollment:	97
Study Start Date:	January 2005
Study Completion Date:	July 2007
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets 1 tablet daily
2: Active Comparator	Drug: levonorgestrel/EE 0.15/0.03 mg tablets and placebo 1 tablet daily

Eligibility

Ages Eligible for Study:	18 Years to 40 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Moderate to severe menstrual-related pain
Regular spontaneous menstrual cycles

Exclusion Criteria:

Any contraindication to the use of oral contraceptives
Treatment with an oral contraceptive in the last 3 months
Previous treatment failure with an extended oral contraceptive regimen

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00196365

Locations

United States, Alabama
Duramed Investigational Site
Huntsville, Alabama, United States, 35801
United States, Arizona
Duramed Investigational Site
Phoenix, Arizona, United States, 85032
United States, California
Duramed Investigational Site
San Diego, California, United States, 92108
United States, Colorado
Duramed Investigational Site
Denver, Colorado, United States, 80202
United States, Florida
Duramed Investigational Site
Tampa, Florida, United States, 33607
United States, Georgia
Duramed Investigational Site
Decatur, Georgia, United States, 30034
United States, New Jersey
Duramed Investigational Site
Moorestown, New Jersey, United States, 08057
United States, North Carolina
Duramed Investigational Site
Charlotte, North Carolina, United States, 28222
United States, Ohio
Duramed Investigational Site
Columbus, Ohio, United States, 43213
Duramed Investigational Site
Columbus, Ohio, United States, 43205
United States, Oregon
Duramed Investigational Site
Medford, Oregon, United States, 97504
United States, Pennsylvania
Duramed Investigational Site
Philadelphia, Pennsylvania, United States, 19114
United States, Tennessee
Duramed Investigational Site
Memphis, Tennessee, United States, 38120
United States, Utah
Duramed Investigational Site
Salt Lake City, Utah, United States, 84124
United States, Virginia
Duramed Investigational Site
Norfolk, Virginia, United States, 23507
Duramed Investigational Site
Newport News, Virginia, United States, 23602
United States, Washington
Duramed Investigational Site
Spokane, Washington, United States, 99207
Duramed Investigational Site
Tacoma, Washington, United States, 98405

Sponsors and Collaborators

Duramed Research

Investigators

Study Chair:

Duramed Protocol Chair

Duramed Research, Inc.

More Information

No publications provided

Responsible Party:	Duramed Research, Inc. ( Duramed Protocol Chair )
Study ID Numbers:	DR-PSE-305
Study First Received:	September 12, 2005
Last Updated:	February 29, 2008
ClinicalTrials.gov Identifier:	NCT00196365 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Duramed Research:

cyclic pelvic pain
dysmenorrhea

Study placed in the following topic categories:

Contraceptive Agents
Estradiol valerate
Contraceptives, Oral
Contraceptive Agents, Female
Ethinyl Estradiol
Pain
Estradiol 17 beta-cypionate
Hormones

Estradiol
Signs and Symptoms
Pelvic Pain
Dysmenorrhea
Menstruation Disturbances
Estradiol 3-benzoate
Levonorgestrel
Polyestradiol phosphate

Additional relevant MeSH terms:

Contraceptive Agents
Contraceptives, Oral
Physiological Effects of Drugs
Contraceptive Agents, Female
Pain
Reproductive Control Agents
Pharmacologic Actions
Signs and Symptoms

Pelvic Pain
Pathologic Processes
Dysmenorrhea
Menstruation Disturbances
Therapeutic Uses
Levonorgestrel
Contraceptives, Oral, Synthetic

ClinicalTrials.gov processed this record on July 02, 2009